Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates
| Autor: | Francisco Bandeira, Thyciara Fontenele Marques, Mario de Almeida Pereira Coutinho, Luiz Griz, Isabel Oliveira de Sousa, Erik Trovão Diniz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Osteoporosis Osteocalcin osteocalcin Thiophenes Strontium ranelate ranelato de estrôncio Bone Density Teriparatide β-CTX strontium ranelate medicine Organometallic Compounds osteocalcina Humans In patient bone remodeling Aged Gynecology teriparatide Bone Density Conservation Agents Diphosphonates teriparatida business.industry osteoporose General Medicine medicine.disease osteoporosis remodelação óssea Female business Bone marker Previously treated Peptides Biomarkers medicine.drug |
| Zdroj: | Arquivos Brasileiros de Endocrinologia & Metabologia v.54 n.2 2010 Arquivos Brasileiros de Endocrinologia & Metabologia Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM Arquivos Brasileiros de Endocrinologia & Metabologia, Volume: 54, Issue: 2, Pages: 244-249, Published: MAR 2010 |
| Popis: | OBJECTIVE: To evaluate the responses of serum β-CTX and osteocalcin in patients who were undergoing treatment with teriparatide or strontium ranelate (SR). SUBJECTS AND METHODS: We analyzed 14 patients (12 women and 2 men; mean age of 71 years) taking teriparatide, and 13 female patients (mean age of 70 years) taking SR; all the patients having previously been on bisphosphonates. Serum β-CTX and osteocalcin levels were determined before and after the first and third months of teriparatide treatment and up to the fourth month of treatment with SR. RESULTS: We observed an initial significant increase in osteocalcin levels during the first month (165%, p = 0.01) followed by a peak of β-CTX (180%, p = 0.02) after the third month of treatment with teriparatide. An increase in these markers was also observed with SR: 49% in osteocalcin (p = 0.002) and 80% in β-CTX (p = 0.008). CONCLUSION: SR had a predominantly short-term bone-forming effect in postmenopausal women with osteoporosis previously treated with bisphosphonates in a lesser degree than with teriparatide. OBJETIVO: Avaliar as respostas do β-CTX e osteocalcina séricos em pacientes que foram submetidas a tratamento com teriparatida ou ranelato de estrôncio (RE). SUJEITOS E MÉTODOS: Analisaram-se 14 pacientes (12 mulheres e 2 homens; idade média 71 anos) tomando teriparatida, e 13 mulheres (idade média 70 anos) tomando RE; todos os pacientes haviam previamente tomado bisfosfonatos. Níveis séricos de β-CTX e osteocalcina foram determinados antes e após o primeiro e terceiro meses de tratamento com teriparatida e no quarto mês de tratamento com RE. RESULTADOS: Observou-se um aumento inicial significativo nos níveis de osteocalcina no primeiro mês (165%, p = 0,01), seguido por um pico do β-CTX (180%, p = 0,02) após o terceiro mês de tratamento com teriparatida. Aumento nesses marcadores também foi observado com RE: 49% na osteocalcina (p = 0,002) e 80% no β-CTX (p = 0,008). CONCLUSÃO: RE teve um efeito predominantemente na formação óssea a curto prazo em mulheres na pós-menopausa com osteoporose tratadas previamente com bisfosfonatos em menor grau que a teriparatida. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|